Home > Gastroenterology > Cancer research advances presented at ASCO 2022 -part 2

Cancer research advances presented at ASCO 2022 -part 2

ASCO 2022
Reuters - 06/06/2022 - The following are summaries of some of the cancer research advances being presented the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Liquid biopsy shows who can skip chemotherapy after colon surgery Liquid biopsy can help identify patients with stage II colon cancer who do not need chemotherapy to prevent recurrence after surgery, according to results of a 455-patient study presented on Saturday. Among patients in the study who were tested via liquid biopsy, 15% ended up receiving chemotherapy versus 28% whose risk was determined using standard diagnostics. Two years later, rates of survival without recurrence were similar, at roughly 93%, in both groups, the researchers reported at ASCO 2022 and in 

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on